A randomized trial of memantine as treatment for spasticity in multiple sclerosis

Mehta, Lahar R.; McDermott, Michael P.; Goodman, Andrew D.; Schwid, Steven R.
February 2010
Multiple Sclerosis (13524585);Feb2010, Vol. 16 Issue 2, p248
Academic Journal
We report the results of a single center randomized, double-blind, placebo-controlled, parallel group trial of memantine in adults with multiple sclerosis and spasticity conducted over 12 weeks. Eligible MS patients had to have an Ashworth spasticity rating of 2 or higher in at least one lower extremity muscle group. Subjects were randomized to receive either placebo or memantine 10 mg twice a day. The primary outcome measure for efficacy was the change in Ashworth Spasticity Scale Score. Although well tolerated, memantine treatment did not demonstrate efficacy in treatment of spasticity in this 12-week small exploratory study.


Related Articles

  • A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma. Cui, Chuanliang; Mao, Lili; Chi, Zhihong; Si, Lu; Sheng, Xinan; Kong, Yan; Li, Siming; Lian, Bin; Gu, Kangsheng; Tao, Min; Song, Xin; Lin, Tongyu; Ren, Xiubao; Qin, Shukui; Guo, Jun // Molecular Therapy;Jul2013, Vol. 21 Issue 7, p1456 

    Endostatin is a potent endogenous angiogenic inhibitor with implicated antitumor activity. However, efficacy of recombinant human endostatin (rhES) in clinical trials is controversial, and application of rhES in treatment of metastatic melanoma awaits further investigations. This phase II trial...

  • Randomized double blind placebo control studies, the "Gold Standard" in intervention based studies. Misra, Shobha // Indian Journal of Sexually Transmitted Diseases;Jul-Dec2012, Vol. 33 Issue 2, p131 

    Studies follow a hierarchy in terms of the quality of evidence that they can provide. Randomized double blind placebo control (RDBPC) studies are considered the "gold standard" of epidemiologic studies. And the same is discussed at length in this paper taking example of a real journal article...

  • A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. Kappos, L.; Radue, E. W.; O'Connor, P. // Current Medical Literature: Multiple Sclerosis;2010, Vol. 2 Issue 2, p52 

    In this article, the authors discuss a placebo-controlled trial of fingolimod in patients with relapsing multiple sclerosis (MS). They say that the study assessed fingolimod's efficacy in 1272 relapsing-remitting MS (RRMS) patients, who randomly received oral fingolimod capsules at doses of 0.5...

  • Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis. Comi, Giancarlo; Filippi, Massimo; Rocca, Maria A.; Jeffery, Douglas; Kappos, Ludwig; Montalban, Xavier; Boyko, Alexey // New England Journal of Medicine;3/15/2012, Vol. 366 Issue 11, p1000 

    Background: Two proof-of-concept clinical trials have provided evidence that laquinimod reduces disease activity in patients with relapsing�remitting multiple sclerosis. Methods: We conducted a randomized, double-blind, phase 3 study at 139 sites in 24 countries. A total of 1106 patients...

  • 4-Aminopyridin (Fampridin). Husseini, L.; Leussink, V. I.; Kieseier, B. C.; Hartung, H. P. // Der Nervenarzt;Feb2010, Vol. 81 Issue 2, p203 

    Mobility limitation is a frequent clinical symptom of multiple sclerosis (MS) that poses a therapeutic challenge. For years results of animal experiments and clinical experience have indicated that the potassium channel blocker 4-aminopyridine improves axonal excitatory circuits and thus...

  • PAW25 A single-centre, pilot, randomised controlled trial of recombinant human erythropoietin in primary progressive multiple sclerosis. I Karpha // Journal of Neurology, Neurosurgery & Psychiatry;Nov2010, Vol. 81 Issue 11, pe30 

    INTRODUCTION: There is currently no disease modifying therapy for PPMS, which constitutes 10–15% of MS cases. rhEPO is has previously been suggested to have a neuroprotective role in an open label, exploratory study of rhEPO in progressive MS. METHODS: A pilot randomised controlled trial...

  • THC:CBD Spray and MS Spasticity Symptoms: Data from Latest Studies. Rekand, Tiina // European Neurology;Jan2014 Supplement, Vol. 71, p4 

    New clinical experience with 9-delta-tetrahydocannabinol (THC) and cannabidiol (CBD) oromucosal spray (Sativex®) involving more than an additional 1,000 patients with MS spasticity (approximately 150 in clinical studies and 900 in post-marketing surveillance studies) have become available in...

  • THC:CBD Observational Study Data: Evolution of Resistant MS Spasticity and Associated Symptoms. Trojano, Maria // European Neurology;Feb2016 Supplement, Vol. 75, p4 

    Background: The prospective observational MObility ImproVEment (MOVE) 2 study is collecting real-life clinical outcomes data on patients with treatment-resistant multiple sclerosis (MS) spasticity treated with THC:CBD oromucosal spray in routine clinical practice. The MOVE 2 study has been...

  • Safety, tolerability, and pharmacokinetics of the novel αv-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses. Uhl, Wolfgang; Zühlsdorf, Michael; Koernicke, Thomas; Forssmann, Ulf; Kovar, Andreas // Investigational New Drugs;Apr2014, Vol. 32 Issue 2, p347 

    Purpose We evaluated the safety, tolerability, and pharmacokinetics (PK) of EMD 525797 (DI17E6), a humanized monoclonal antibody targeting αv-integrins, in healthy subjects. Methods In this first-in-human, double-blind, placebo-controlled, randomized Phase 1 study, healthy male volunteers...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics